Patients Bringing parity to infertility, with Jean Duvall During JPM2026, pharmaphorum spoke with Jean Duvall, CEO of Repronovo, a company that’s working on new infertility treatments for men and women.
Market Access Five Takeaways from JP Morgan Week 2026 JP Morgan Week may not have produced megadeals this year, but it still yielded plenty of food for thought. Here's five quick insights from San Fran.
Sales & Marketing Rewiring commercialisation to meet the moment, with Helen Sa... At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.
Digital JPM2026: AI diagnostics and translational research, with And... On the sidelines of JPM2026, pharmaphorum spoke with Andrew Beck, co-founder and CEO at PathAI, about AI diagnostics in pathology.
Oncology Unlocking the future of epigenetics, with Carlos Buesa Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.
News JPM: Novo Nordisk CEO gives insight into new strategy Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.